Skip to Content

Tilray Brands Inc TLRY

Morningstar Rating
CAD 2.39 +0.02 (0.84%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Tilray Earnings: Slashing Our Fair Value Estimate on Slower Revenue Growth and Margin Contraction

No-moat Tilray issued disappointing (February-ended) fiscal 2024 third-quarter results, including slower revenue growth and margin contraction. Changes to our forecast alone imply a valuation reduction roughly in line with the ensuing market price decline of about 21%. In addition, we’ve removed all contribution to our fair value estimate from Tilray’s ownership of US multistate operator Medmen’s senior secured convertible notes, as a complete write-off of the investment seems inevitable. The asset had composed about 20% of our fair value estimate. Thus, due to these two factors, we are cutting our fair value estimates to $2/CAD 2.70 from $3.10/CAD 4.20. As reflected in our Very High Uncertainty Rating, changes to our forecast can have dramatic effects on our fair value estimates, especially as Tilray has yet to achieve positive free cash flow. Shares trade close to our updated fair value estimates.

Price vs Fair Value

TLRY is trading at a 11% discount.
Price
CAD 2.39
Fair Value
CAD 6.90
Uncertainty
Very High
1-Star Price
CAD 1.26
5-Star Price
CAD 6.13
Economic Moat
Mwcwj
Capital Allocation
Kfjdprt

Bulls Say, Bears Say

Bulls

Tilray's better financial health and profitability lead compared with Canadian peers positions it to lead its home market.

Bears

The existence of the illicit market limits the potential price increases Tilray can push through to consumers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLRY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CAD 2.37
Day Range
CAD 2.332.46
52-Week Range
CAD 1.974.64
Bid/Ask
CAD 2.37 / CAD 2.37
Market Cap
CAD 1.85 Bil
Volume/Avg
2.3 Mil / 2.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.81
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.09%

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Competitors

Valuation

Metric
TLRY
CRON
ACB
Price/Earnings (Normalized)
Price/Book Value
0.430.840.80
Price/Sales
1.8110.521.16
Price/Cash Flow
Price/Earnings
TLRY
CRON
ACB

Financial Strength

Metric
TLRY
CRON
ACB
Quick Ratio
0.9621.681.79
Current Ratio
1.9222.543.79
Interest Coverage
−4.39
Quick Ratio
TLRY
CRON
ACB

Profitability

Metric
TLRY
CRON
ACB
Return on Assets (Normalized)
−13.42%−0.53%
Return on Equity (Normalized)
−17.13%−0.55%
Return on Invested Capital (Normalized)
−14.23%−4.90%
Return on Assets
TLRY
CRON
ACB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ACylrfkmcmMps$70.0 Bil
MKKGY
Merck KGaA ADRWsfbgqmdzxJmqtqr$68.1 Bil
HLN
Haleon PLC ADRXylrdydrXqh$36.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRFnfpgpfzfByp$14.3 Bil
VTRS
Viatris IncNsfykptnNbnz$13.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRKmhcxkrsMkdn$12.0 Bil
CTLT
Catalent IncLtdtzpwwxRhlfp$10.1 Bil
PRGO
Perrigo Co PLCLsfrrrxlCssqr$4.1 Bil
CURLF
Curaleaf Holdings IncGxmnhdtJxvl$3.7 Bil
PBH
Prestige Consumer Healthcare IncQxnmtjxXpydn$3.4 Bil

Sponsor Center